{"ticker": {"uuid": "2edc0cda-d69c-4b3b-96ab-13b527cb8621", "symbol": "RXRX", "name": "Recursion Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPdFVJOVZ4WUY2OVNRNnk2R1ZBdnRVNVJKa2RzQS1PY2J3SzVDWFpkY2tqakVSb0djUkZnVlhmS2pCWWhnZ01VcnpoaTNZSGhVaEZ6eEFCakJ2OWtGaU8yT1dIbTBmcmJFbVE2RzFaYlB6WVBWS240WndoTzVFbGU0cDl2WkVVX09wXzhTYklldzZKTktOM29YUGNxa0tDanc5OG4wQ0lPVG1XMjh5?oc=5", "source_name": "Market source", "published_at": "2026-07-14T21:50:03+00:00", "published_display": "14 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has \u2018Reached An Inflection Point\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNd0hKNF84emhiVl9UbDhYOWQtdl9jV2JYZmduUy1QV2haQ3RBeXlpWjNiMDV3SUpBZVFGOEE2Tmd5QUNYV2lDLVdFOVg3SFZ4enA1YnJMWmVVaUl2VUVOSlZnSUtjdnBoY1ZaZURVVm84RTU0UHdXaUFXbTZOYmo5S3BRSnlvakVraElJZmZVOUtYeEQ4em1SUVJkdG1lcHh5U0FmRzMwX0dua0FjdEE5TGRzMXUxX1phLUpQWHRDTXZWR205cm9kQUUwbUlVQ0RmalBB?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T14:44:00+00:00", "published_display": "14 Jul 2026 14:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Recursion Pharmaceuticals, Inc. \u2013 NASDAQ:RXRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOMGtKMFBmU1BSbkdSdFFKMTZyaU55dGVtOFdXZXJmdkljLWwxWVJxRUtQdEVJZVVGekRCN25NNHk2QkE0QTNRdXBXNTd2VWwyUkVDeDBFdXhfV3JVcjhfcWNKOVVzdUdFdjc4SHhSZXNaN2tGNjhUdU5PNEJ5UHlhUTVqSFF6VmxNRGc2NzEzb0ZwTERIMktaYVpDb0FXdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T18:53:13+00:00", "published_display": "13 Jul 2026 18:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Recursion Pharmaceuticals (RXRX) Highlights Clinical Progress, Is The Stock Fully Priced?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-11T19:25:57+00:00", "published_display": "11 Jul 2026 19:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals director Borgeson sells $158,500 stock By Investing.com", "summary": "Recursion Pharmaceuticals director Blake Borgeson sold 40,000 shares of Class A Common Stock for a total of $158,500, pursuant to a Rule 10b5-1 trading plan. The sale occurred on July 7, 2026, with shares sold between $3.95 and $4.00. This transaction leaves Borgeson with 6,218,2", "url": "https://m.in.investing.com/news/stock-market-news/recursion-pharmaceuticals-director-borgeson-sells-158500-stock-93CH-5490450?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-10T20:41:04", "published_display": "10 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNbXpjT29EVjlXQTRDY2FRVk41TjF1Nlh0RTcxWW9Dc1R6VDFjVUtNLXVEamlhUGRQNVk0bnV0cEtyNElvNEtMWUxBcUtKOEVXbVdwV0dTVldTc0Q4X3hWOWt0VnhBUElRdDNRcG5uVlRpNmlPbVdIMTg2OEZsVWt1VnpTaEt3cUh0Ulh1RHFMcXljendVLXZpdFR0by1yWkM3XzNkZWNiVlNiZFVn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T17:37:00+00:00", "published_display": "10 Jul 2026 17:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) director sells 40,000 shares in 10b5-1 trade", "summary": "Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 40,000 shares of Class A common stock on July 7, 2026, at a weighted average price of $3.9625 per share, totaling approximately $159,000. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-422dd25714d8.html", "source_name": "Stock Titan", "published_at": "2026-07-10T09:39:51", "published_display": "10 Jul 2026 09:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQM2VTUEpBS1RvYWZndWx0M1hLb0p4dWFFclhzMjFEVjVqaGpqS3NDb2ZjR3pxUGRwazZNdlZSX1hUYWVDQm4wcmlYZzJ5VkZoMmNscGlYeDZzS0wyMkp6TmVWdGktSWJyT0dXWWhZZWpHaXk0WXlzWmY2azZYYktUdHBjUG5IQmYySUMyOXVJb0FWZFpJdXI3SGMyQU91Uk15TjQ3bQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T17:29:09+00:00", "published_display": "09 Jul 2026 17:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-recursion-pharmaceuticals-rxrx-215004097.html", "source_name": "Zacks", "published_at": "2026-07-08T21:50:04+00:00", "published_display": "08 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Recursion (RXRX) Gaining Lasting Strategic Credibility From Its Expanded Russell Index Presence?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T18:42:48+00:00", "published_display": "07 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (NASDAQ:RXRX) beats out biotech funds as filings, spending become focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOWFJwY1pORVYybjVVdWRsR3ZnUUtMRlJlUFpsSHpzaUY4RGxPSUxBaE9mV3pUel84ZUN3YzNzZ0RKUXVKSEdJTnM4SmI2NUhkZUdqWERmbHVMU2Y3aGxfUFgydDRnSGg5Ymo4bTVZRkpaWWpTNm5ZeEdhdUk3djc4VGd3QnZNMlFON0dEeFZta3IxSkk1Sm9saFVtVUY1b293ODdTSmVNN1BGaHIzdWYzV0FaeEY?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-06T08:08:12+00:00", "published_display": "06 Jul 2026 08:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/recursion-pharmaceuticals-rxrx-8-0-010926467.html", "source_name": "Simply Wall St.", "published_at": "2026-07-06T01:09:26+00:00", "published_display": "06 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals Stock (RXRX) Opinions on Technical Consolidation", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNdDh6TXFrVlQ1U0poMkNveE1mVWM5NmVtSkVLamF5dDZxMXVvUkZDZkFwOTZ5T0d1TnRhOGk2ZnRmUjVtMVN5RFFLMlhscWQ5TVZOaE9Qc1FybzJJOFpfMGVWWFR1Z3NpUHA2Nml6RWkzZ3k1ZHdRVkVGUFFnUVpxSDR4OVJDckpac0dCVTg1bE5VcDRYR0pMdkktSE16VS1VTjlDR3dnSHZZaXVLNVREQg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-05T14:03:00+00:00", "published_display": "05 Jul 2026 14:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNa1hrRnktb2hsS0I5VDhXam4zRXpyUFNFd1FGSGFCcl9rQlpPanpadmo2dEZqU2lXeVFOSVNWTXNfMzBkMnRGNnVvMmFscXhsamgzWFlPdmR5ZV9BVE9JNFVLLVpSMXNEVFRhTHBPQkJqSXI4d3pkTnBic2ozWlVkTEdNWGk1ZUFUUlRnbVVxbElEWHMzbHZXbU5NemVBcVg5VHF3bUVZa01Scjg?oc=5", "source_name": "Market source", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/b22bde8f-371f-3d11-a89f-ca3035c728e4/dyne-therapeutics-vs..html", "source_name": "Motley Fool", "published_at": "2026-07-04T13:41:09+00:00", "published_display": "04 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/2ee1b0d5-41d6-3a98-9c77-2ed73e01beb4/moderna-vs.-recursion%3A-which.html", "source_name": "Motley Fool", "published_at": "2026-07-03T15:34:15+00:00", "published_display": "03 Jul 2026 15:34", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares", "summary": "Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 5,109 Class A shares at no cash cost under the company\u2019s Outside Director Compensation Policy. Following this award, Dar directly holds 240,764 Class A shares. This transaction was reported in a Form 4 filing and ca", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-924cb5c401f7.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:09:18", "published_display": "02 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant", "summary": "Recursion (NASDAQ: RXRX) director Dean Y. Li has received an equity grant of 3,747 Class A shares as compensation under the company\u2019s Outside Director Compensation Policy. This grant increases his direct holdings to 1,473,329 Class A shares. Additionally, Li indirectly holds 421,", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-2b971e2d556c.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:09:18", "published_display": "02 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Christopher C. Gibson lists multiple Class A sales (RXRX)", "summary": "Christopher C. Gibson, an insider at Recursion Pharmaceuticals, Inc. (RXRX), has filed a Form 144 notice for proposed sales of Class A common stock. The filing details several disposition dates and share quantities, including a significant 100,000 share entry dated July 1, 2026, ", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-181a59cb8e83.html", "source_name": "Stock Titan", "published_at": "2026-07-02T16:55:11", "published_display": "02 Jul 2026 16:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX (NASDAQ: RXRX) insider sale notice \u2014 100,000 Class A shares", "summary": "Recursion Pharmaceuticals (NASDAQ: RXRX) has filed a Form 144 disclosing a prospective sale of 100,000 Class A shares resulting from restricted stock vesting on May 15, 2025. The filing also notes previous dispositions by Christopher C. Gibson, including 340,440 shares sold for o", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-2c39764b915f.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:39:49", "published_display": "01 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNR1dwU3ZUbkZ4d1A1SXN0eEg2WDBlT1pxNDlxbjNHYVI0Vk9oUDA4NDJIOHdjQlgtRjNrLVViVU1GcUxCTWZMVnpaeUNXRnhMeDVJSThFNnpqYzhxTTd3UjJfUnpjWXU2bWJnME1RbzZfV2FNZWZuRWJpRkhfVG0xMXJuTEthYTA3NUI4OWhHVlVidjNzR2w1Y0psUmU4V1R3VkhOZHdyMWhjOEhkQk0wMkIxZ0V1UjAyUmM3OFhvQlZvN3RIRF9abnNzM09uRFdFeFJoalphVDZMRHVWN0VIZzRR?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals Stock (RXRX) Opinions on ARK Invest's Recent Share Purchase", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQy1EQkxoUVlXN3czcHk1d0c5TlZ5b25fWm1hZ01ZUVFCc0xOekxtZ3Zwc0Vjc3lLWFVqZ1ZsLVQ5eXhqb1EwVm90cDIxd3hEc1BuZG1vMVd3ZVdRemlPMVpFTjl3OTlYTEFjN0dvYjZiY1M0NC11UEJtWm9VNG1Pb2NyWERrMUpVSkdpaGUzdDBTTUluSHFGRThvN29SWmVxVUVlZzFiNnExU0ZSb0hvMkVHMzEta1dHbkN0a01SWHhRUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:RXRX)", "summary": "This article provides an overview of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions regarding the stock's ticker, price volatility, earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-RXRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:57", "published_display": "26 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8RL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Recursion Pharmaceuticals, Inc. Class A (8RL) stock, including a price target of 5.69 EUR based on analyst estimates. It outlines key financial metrics such as recent earnings and revenue, and provides information on employee count and EBITDA.", "url": "https://www.tradingview.com/symbols/SWB-8RL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:57", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals Stock Short Interest Rises to 36.75% | RXRX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPUWFqcTBzYVpDV2ZOd0xLb0Z2R3l1X09TcXI3X01vbnFRd1dhRzh2RnZCaF9ubHlrc1VscTBNMUllOWZ2N09pZkxIVy1RbllYVFBsSDZ3ZVZDR1kwTTBTTi1FdzZkMFQ5NmMyUU9MUHF5RFhwNExDSTI4dFVRZU53bnV3dVY3dVg3eW5fMWZmdGxjMmFiQVM1OUZrcnlEQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Recursion Pharmaceuticals, Inc. (RXRX) stock, including analyst price targets and ratings. It details the company's financial performance, such as recent earnings and revenue, and answers common questions about its stock performance, market ca", "url": "https://www.tradingview.com/symbols/BX-RXRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T04:09:24", "published_display": "26 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOOEpKOENaUGtoTm5xaVdTLVdhSENyZjBxeUVyYUs3Q3NhTlk0bkRpUFdZRTFfWUw3WnMxcS1LSVNxUC15em4tZzJsQmxzeWJESWVLT1FkX1VFcVN1MmRvX3I0VXpTSjJMdWxLYVlmZTFyTXpQN25SU0hRWG8zWUVkNjFVVWRqWXduc1ZnTmRSQVQ5em1HTzVhN0l0enBWRUtoNTJDaVY0c2VtYVk4aXc?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director receives 88,424-share restricted stock grant", "summary": "Recursion Pharmaceuticals (NASDAQ: RXRX) director Robert Hershberg was granted 88,424 restricted stock units (RSUs) as a routine award under the company\u2019s Outside Director Compensation Policy. These RSUs vest on the earlier of June 17, 2027, or the day before the company\u2019s 2027 a", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-029d56158593.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:26", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director gets 88,424 RSUs, sells 3,963 shares", "summary": "Recursion Pharmaceuticals, Inc. director Namandje Bumpus received a grant of 88,424 restricted stock units (RSUs) on June 17, 2026, which vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholders\u2019 meeting. Concurrently, on June 18, 2026, Bumpus sold 3,9", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-2dd9159873a3.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:12:35", "published_display": "23 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director Elaine Sun receives 88,424 restricted stock units", "summary": "Recursion Pharmaceuticals (NASDAQ: RXRX) director Elaine Sun has been granted 88,424 restricted stock units (RSUs) as an equity award, with no cash cost, under the company\u2019s Outside Director Compensation Policy. These RSUs will vest on the earlier of June 17, 2027, or the day bef", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-ce95735cbb59.html", "source_name": "Stock Titan", "published_at": "2026-06-23T01:39:26", "published_display": "23 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (RXRX) director Zavain Dar granted 88,424 restricted stock units", "summary": "Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 88,424 restricted stock units (RSUs) for board service. These RSUs, valued at $0.00 per share, will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholder meeting, contingent on continue", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-dc80c6c6cf27.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:26", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director gets 88,424 restricted stock units", "summary": "Recursion Pharmaceuticals (NASDAQ: RXRX) director Franziska Michor was granted 88,424 restricted stock units as compensation under the company's Outside Director Compensation Policy. These units were granted at $0.00 per share and will vest on June 17, 2027, or the day before the", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-8d1c13cf7754.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:26", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director Dean Y. Li granted 88,424 RSUs, updates holdings", "summary": "Recursion (NASDAQ: RXRX) director Dean Y. Li was granted 88,424 restricted stock units (RSUs) as part of the company's Outside Director Compensation Policy. These RSUs, valued at $0.00 per share, are set to vest on June 17, 2027, or the day before the 2027 Annual Meeting of Stock", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-54f57d2b93ef.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:26", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (RXRX) director receives 88,424 restricted stock units award", "summary": "Recursion Pharmaceuticals (RXRX) director Blake Borgeson was granted 88,424 restricted stock units of Class A common stock under the company\u2019s Outside Director Compensation Policy. These units will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholde", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-053e24d8f932.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:26", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Proxy filing Summary", "summary": "Recursion Pharmaceuticals (RXRX) will hold its annual meeting virtually on June 17, 2026, where shareholders will vote on the election of two Class II directors, executive compensation, and auditor ratification. The company, a clinical-stage TechBio firm, uses AI for drug discove", "url": "https://quartr.com/events/recursion-pharmaceuticals-inc-rxrx-proxy-filing_oje5fnnj", "source_name": "Quartr", "published_at": "2026-06-20T00:39:34", "published_display": "20 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) investors back board nominees and PwC as 2026 auditor", "summary": "Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shareholders approved all management proposals at their 2026 annual meeting on June 17, 2026. Shareholders re-elected Class II directors Najat Khan, Ph.D., and Franziska Michor, Ph.D., and advisory approved executive compensation. Th", "url": "https://www.stocktitan.net/sec-filings/RXRX/8-k-recursion-pharmaceuticals-inc-reports-material-event-89f780a220d1.html", "source_name": "Stock Titan", "published_at": "2026-06-19T00:39:34", "published_display": "19 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX (NASDAQ) proposed resale of multiple 40,000-share blocks between Mar\u2013Jun 2026", "summary": "RXRX (Recursion Pharmaceuticals, INC.) has filed a Form 144, indicating proposed resales of Class A founder shares. The filing details multiple 40,000-share blocks with potential trade dates spanning from March to June 2026, each with an associated dollar value. Fidelity Brokerag", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-c9a2980302a5.html", "source_name": "Stock Titan", "published_at": "2026-06-19T00:09:59", "published_display": "19 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Christopher C. Gibson sells six 40,000-share lots (RXRX) across Mar\u2013Jun 2026", "summary": "Christopher C. Gibson, an insider at Recursion Pharmaceuticals (RXRX), filed a Form 144 detailing six separate sales of 40,000 Class A shares each between March and June 2026. The filing also indicates scheduled restricted stock vesting events for Class A shares in 2025 and 2026.", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-fc478c99337b.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:09:20", "published_display": "18 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX (NASDAQ) affiliate files Form 144 to sell 3,963 Class A shares", "summary": "An affiliate of Recursion Pharmaceuticals (RXRX) has filed a Form 144, indicating an intent to sell 3,963 Class A shares resulting from restricted stock vesting on June 18, 2026. This filing also discloses a prior sale of 4,386 Class A shares by Namandje Bumpus on June 3, 2026. T", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-b9f26ac2a192.html", "source_name": "Stock Titan", "published_at": "2026-06-18T13:40:32", "published_display": "18 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) CFO covers taxes with 5,396 withheld shares", "summary": "Recursion Pharmaceuticals' CFO, Ben R. Taylor, reported a tax-related disposition where 5,396 shares of Class A Common Stock were withheld to cover tax obligations stemming from restricted stock units. The shares were withheld at a price of $3.15 per share. Following this transac", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-d55499100731.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:10:36", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Stock Could Be 67% Overvalued After Pipeline Updates", "summary": "Recursion Pharmaceuticals (RXRX) is gaining attention due to recent clinical updates and an upcoming presentation at the Goldman Sachs Global Healthcare Conference, leading to a recent share price increase. Despite this, some analyses suggest the stock is significantly overvalued", "url": "https://www.sahmcapital.com/news/content/recursion-pharmaceuticals-rxrx-stock-could-be-67-overvalued-after-pipeline-updates-2026-06-16", "source_name": "Sahm", "published_at": "2026-06-16T12:40:35", "published_display": "16 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Early Safety Data And FDA Signals Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX)", "summary": "Recursion Pharmaceuticals' investment case is being reshaped by early safety data for REC-1245 in solid tumors and anticipated FDA feedback on REC-4881, which are key catalysts for its AI-driven drug discovery platform. While the initial safety profile of REC-1245 is positive, in", "url": "https://www.sahmcapital.com/news/content/early-safety-data-and-fda-signals-might-change-the-case-for-investing-in-recursion-pharmaceuticals-rxrx-2026-06-13", "source_name": "Sahm", "published_at": "2026-06-13T23:10:36", "published_display": "13 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock", "summary": "Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of RXRX stock totaling $84,459 on June 5, 2026, through a pre-planned trading arrangement. Despite this sale, Khan still holds over 2.1 million shares, and the company is considered undervalued by InvestingPro. The compa", "url": "https://www.investing.com/news/insider-trading-news/recursion-pharmaceuticals-ceo-najat-khan-sells-84459-in-rxrx-stock-93CH-4729290", "source_name": "Investing.com", "published_at": "2026-06-08T08:10:18", "published_display": "08 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After Positive AI Drug Data And Extended Cash Runway", "summary": "Recursion Pharmaceuticals (RXRX) saw its stock rise by 9.5% following positive early clinical data from its AI-driven drug discovery programs and a reduced cash burn, extending its capital runway into early 2028. This progress suggests its integrated TechBio model is yielding tan", "url": "https://www.sahmcapital.com/news/content/why-recursion-pharmaceuticals-rxrx-is-up-95-after-positive-ai-drug-data-and-extended-cash-runway-2026-06-04", "source_name": "Sahm", "published_at": "2026-06-06T08:40:12", "published_display": "06 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com", "summary": "Najat Khan, CEO of Recursion Pharmaceuticals, sold 23,588 shares of RXRX stock for $84,459 on June 5, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, Khan directly holds over 2.17 million shares, and the company has a market cap of $1.77 billion. The article also", "url": "https://m.za.investing.com/news/insider-trading-news/recursion-pharmaceuticals-ceo-najat-khan-sells-84459-in-rxrx-stock-93CH-4316803?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-06T08:10:34", "published_display": "06 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) CEO sells 23,588 shares in planned Rule 10b5-1 trade", "summary": "Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of Class A Common Stock at a weighted average price of $3.5806 per share under a pre-arranged Rule 10b5-1 trading plan. After the sale, Khan still directly holds a significant 2,175,796 shares. This transaction, detailed", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-aa40cd8c382f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:39:40", "published_display": "05 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxObk5Dbkc3Y0xPSURiQVFuRzRHdHl2b0dDMEIzM3ZrN2x3ZDlKNFA1b1FPRHpMb2Z3MnBKV1NTdzMxSG5FNXpWT1JQd1JCR3NhVF9FZzZSeDZkeFhHSTUxcFVkRVY4Tm5pUEFjRXI4eE5IWW1YRktYUFg3ejZJcU9tNHhjanZ2eXNRT2FTRzdDZTJGUERWdXQ5VUljbDdjZTVPdmc?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Recursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America Securities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOQnI4aGFtR0FiYjgxM2d4UUZhRk4wLUFKc1VYejNQRkxYTW54dnROZHlYbG5hbndGd1FtVHdYbFRxUEJRcGJicVIyTExsZkdUeGhpc19xYU1RUUk5YkNSVnZUTXJSNzcyX1VWNFlhWTdPNjJmZFlsMkZuOFI5QmhGdG1obzJwVk9LSWdKWTlNbnYtTEhwVG9ZSUU1MWlDY1RwRzZPYTBSNGpza1g5S3V6b0ZRS0N3cXYtTXNrc1lGM2dWTEdHdVVLTk00VlZ1ZHJMNTdGTW9pcXFPQUN3cVduTDlhSlNwVnpkVFRYU1pvQ284aEhvMUE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Recursion\u2019s AI Drug Programs Show Early Clinical Progress And Valuation Gap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Q1 Loss Of US$117.5 Million Tests AI Growth Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNUDVWNGhGVnJrNW5XVXdkd1BmTU9LdUY0LXZ0UGVWak1KSmh4Uy01bkkyeWhaTkRPbkh2WnNSYllpRHlnVlV3d05FWF9UOEZZb3N0UlRSX24xeHd0X3dnMy0tTmRCaUtkdDFjZEtIajlyc3RBMFZZQU9QNTBEcVJDRVpuQ19CVlJQb2ltb2lTOFVEZGs2aUNiUVhZQVRjZWQ0QjRzQk5pMGE0a050RlZNTkpONE9MeE8yZWxMRW8yaUdCLXYwbVgwc3ZpTEJRa084WUcycHZUVFJSeE5FMVZyTzhjWEp4RGlKdUlHbFJsY0PSAfYBQVVfeXFMT3lFVHVyRmdVejZBU3B4YUJoWkt4UTJ1RHlmZzk5ZFBVX2pkN25TRWR2NGVzVUl5YU5EX3lCM0Q2MjROeGFJRGZ1d05XczdBM25xNmJBRDBoVERyN3pXeDVUTDJJbWxXaEh1WGlfYTlyY2FiTzJ5Y0p1RnhxTEFKczJxRUY5RGtWN2V2cHV2cjdqVThVN2dNOGdBN1Z4SWNrTzlDcm1jM1JVTm5hSE5rd3VyYlVDNmJlQk1RWGlvUjFnYTUtU1FVdXBvdE5vM2wzSDlrVTdYR1NwRHp2ZW8zZzlKQkxtRWxXYXU3NVBaT3JpbVNobVNB?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMHotNUpHUWhhaFJlWUdXcHAxdDdsLU9QbG9TYm9Vek9ZNTAyVHdCUTR5c3lqZHhfbDJMVTFZMkkzcG40Q0YtdURBa0g3Q096TDJzUkhfMEY2bDA4d3NnM0lpSDBlYjdtVmVyNWM5WFZBeDFkYTFSZnMtdVc0WFVfQXpPaGR4VWhHdVFneEV6bnRESy1hY1paZzRqTHpFY3BuTHhtdDM1RzRIYWI3TFRpUw?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Wide Valuation Range After Recent Volatility", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Christopher Gibson sells Class A shares (NASDAQ: RXRX) in four filings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNnFGT1VVcXpVeDlPdWhEYXRhMmFGTnpwczc5b1BUejRBTFk5dEZJdEZQZmp4WTM1QXdIV2xTVUN6YjVFODlaT2xtOU5uNGU1Rk1nUVFUV255TmJ6Nnl2NlI3dW5oV3hMdzNhRzh1RDd1cHNvZWJWdUF6TEZ2cWNXQzlpVUlzZ0VHSmwtSjBWVG15S3pVTzd2bnpUcmxaLURJWGJUM2Zoc1V3QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPdFVJOVZ4WUY2OVNRNnk2R1ZBdnRVNVJKa2RzQS1PY2J3SzVDWFpkY2tqakVSb0djUkZnVlhmS2pCWWhnZ01VcnpoaTNZSGhVaEZ6eEFCakJ2OWtGaU8yT1dIbTBmcmJFbVE2RzFaYlB6WVBWS240WndoTzVFbGU0cDl2WkVVX09wXzhTYklldzZKTktOM29YUGNxa0tDanc5OG4wQ0lPVG1XMjh5?oc=5", "source_name": "Market source", "published_at": "2026-07-14T21:50:03+00:00", "published_display": "14 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has \u2018Reached An Inflection Point\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNd0hKNF84emhiVl9UbDhYOWQtdl9jV2JYZmduUy1QV2haQ3RBeXlpWjNiMDV3SUpBZVFGOEE2Tmd5QUNYV2lDLVdFOVg3SFZ4enA1YnJMWmVVaUl2VUVOSlZnSUtjdnBoY1ZaZURVVm84RTU0UHdXaUFXbTZOYmo5S3BRSnlvakVraElJZmZVOUtYeEQ4em1SUVJkdG1lcHh5U0FmRzMwX0dua0FjdEE5TGRzMXUxX1phLUpQWHRDTXZWR205cm9kQUUwbUlVQ0RmalBB?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T14:44:00+00:00", "published_display": "14 Jul 2026 14:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Recursion Pharmaceuticals, Inc. \u2013 NASDAQ:RXRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOMGtKMFBmU1BSbkdSdFFKMTZyaU55dGVtOFdXZXJmdkljLWwxWVJxRUtQdEVJZVVGekRCN25NNHk2QkE0QTNRdXBXNTd2VWwyUkVDeDBFdXhfV3JVcjhfcWNKOVVzdUdFdjc4SHhSZXNaN2tGNjhUdU5PNEJ5UHlhUTVqSFF6VmxNRGc2NzEzb0ZwTERIMktaYVpDb0FXdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T18:53:13+00:00", "published_display": "13 Jul 2026 18:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Highlights Clinical Progress, Is The Stock Fully Priced?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-11T19:25:57+00:00", "published_display": "11 Jul 2026 19:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals director Borgeson sells $158,500 stock By Investing.com", "summary": "Recursion Pharmaceuticals director Blake Borgeson sold 40,000 shares of Class A Common Stock for a total of $158,500, pursuant to a Rule 10b5-1 trading plan. The sale occurred on July 7, 2026, with shares sold between $3.95 and $4.00. This transaction leaves Borgeson with 6,218,2", "url": "https://m.in.investing.com/news/stock-market-news/recursion-pharmaceuticals-director-borgeson-sells-158500-stock-93CH-5490450?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-10T20:41:04", "published_display": "10 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNbXpjT29EVjlXQTRDY2FRVk41TjF1Nlh0RTcxWW9Dc1R6VDFjVUtNLXVEamlhUGRQNVk0bnV0cEtyNElvNEtMWUxBcUtKOEVXbVdwV0dTVldTc0Q4X3hWOWt0VnhBUElRdDNRcG5uVlRpNmlPbVdIMTg2OEZsVWt1VnpTaEt3cUh0Ulh1RHFMcXljendVLXZpdFR0by1yWkM3XzNkZWNiVlNiZFVn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T17:37:00+00:00", "published_display": "10 Jul 2026 17:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) director sells 40,000 shares in 10b5-1 trade", "summary": "Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 40,000 shares of Class A common stock on July 7, 2026, at a weighted average price of $3.9625 per share, totaling approximately $159,000. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-422dd25714d8.html", "source_name": "Stock Titan", "published_at": "2026-07-10T09:39:51", "published_display": "10 Jul 2026 09:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQM2VTUEpBS1RvYWZndWx0M1hLb0p4dWFFclhzMjFEVjVqaGpqS3NDb2ZjR3pxUGRwazZNdlZSX1hUYWVDQm4wcmlYZzJ5VkZoMmNscGlYeDZzS0wyMkp6TmVWdGktSWJyT0dXWWhZZWpHaXk0WXlzWmY2azZYYktUdHBjUG5IQmYySUMyOXVJb0FWZFpJdXI3SGMyQU91Uk15TjQ3bQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T17:29:09+00:00", "published_display": "09 Jul 2026 17:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-recursion-pharmaceuticals-rxrx-215004097.html", "source_name": "Zacks", "published_at": "2026-07-08T21:50:04+00:00", "published_display": "08 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Recursion (RXRX) Gaining Lasting Strategic Credibility From Its Expanded Russell Index Presence?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T18:42:48+00:00", "published_display": "07 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (NASDAQ:RXRX) beats out biotech funds as filings, spending become focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOWFJwY1pORVYybjVVdWRsR3ZnUUtMRlJlUFpsSHpzaUY4RGxPSUxBaE9mV3pUel84ZUN3YzNzZ0RKUXVKSEdJTnM4SmI2NUhkZUdqWERmbHVMU2Y3aGxfUFgydDRnSGg5Ymo4bTVZRkpaWWpTNm5ZeEdhdUk3djc4VGd3QnZNMlFON0dEeFZta3IxSkk1Sm9saFVtVUY1b293ODdTSmVNN1BGaHIzdWYzV0FaeEY?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-06T08:08:12+00:00", "published_display": "06 Jul 2026 08:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/recursion-pharmaceuticals-rxrx-8-0-010926467.html", "source_name": "Simply Wall St.", "published_at": "2026-07-06T01:09:26+00:00", "published_display": "06 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals Stock (RXRX) Opinions on Technical Consolidation", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNdDh6TXFrVlQ1U0poMkNveE1mVWM5NmVtSkVLamF5dDZxMXVvUkZDZkFwOTZ5T0d1TnRhOGk2ZnRmUjVtMVN5RFFLMlhscWQ5TVZOaE9Qc1FybzJJOFpfMGVWWFR1Z3NpUHA2Nml6RWkzZ3k1ZHdRVkVGUFFnUVpxSDR4OVJDckpac0dCVTg1bE5VcDRYR0pMdkktSE16VS1VTjlDR3dnSHZZaXVLNVREQg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-05T14:03:00+00:00", "published_display": "05 Jul 2026 14:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNa1hrRnktb2hsS0I5VDhXam4zRXpyUFNFd1FGSGFCcl9rQlpPanpadmo2dEZqU2lXeVFOSVNWTXNfMzBkMnRGNnVvMmFscXhsamgzWFlPdmR5ZV9BVE9JNFVLLVpSMXNEVFRhTHBPQkJqSXI4d3pkTnBic2ozWlVkTEdNWGk1ZUFUUlRnbVVxbElEWHMzbHZXbU5NemVBcVg5VHF3bUVZa01Scjg?oc=5", "source_name": "Market source", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/b22bde8f-371f-3d11-a89f-ca3035c728e4/dyne-therapeutics-vs..html", "source_name": "Motley Fool", "published_at": "2026-07-04T13:41:09+00:00", "published_display": "04 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/2ee1b0d5-41d6-3a98-9c77-2ed73e01beb4/moderna-vs.-recursion%3A-which.html", "source_name": "Motley Fool", "published_at": "2026-07-03T15:34:15+00:00", "published_display": "03 Jul 2026 15:34", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares", "summary": "Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 5,109 Class A shares at no cash cost under the company\u2019s Outside Director Compensation Policy. Following this award, Dar directly holds 240,764 Class A shares. This transaction was reported in a Form 4 filing and ca", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-924cb5c401f7.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:09:18", "published_display": "02 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant", "summary": "Recursion (NASDAQ: RXRX) director Dean Y. Li has received an equity grant of 3,747 Class A shares as compensation under the company\u2019s Outside Director Compensation Policy. This grant increases his direct holdings to 1,473,329 Class A shares. Additionally, Li indirectly holds 421,", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-2b971e2d556c.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:09:18", "published_display": "02 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Christopher C. Gibson lists multiple Class A sales (RXRX)", "summary": "Christopher C. Gibson, an insider at Recursion Pharmaceuticals, Inc. (RXRX), has filed a Form 144 notice for proposed sales of Class A common stock. The filing details several disposition dates and share quantities, including a significant 100,000 share entry dated July 1, 2026, ", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-181a59cb8e83.html", "source_name": "Stock Titan", "published_at": "2026-07-02T16:55:11", "published_display": "02 Jul 2026 16:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX (NASDAQ: RXRX) insider sale notice \u2014 100,000 Class A shares", "summary": "Recursion Pharmaceuticals (NASDAQ: RXRX) has filed a Form 144 disclosing a prospective sale of 100,000 Class A shares resulting from restricted stock vesting on May 15, 2025. The filing also notes previous dispositions by Christopher C. Gibson, including 340,440 shares sold for o", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-2c39764b915f.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:39:49", "published_display": "01 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNR1dwU3ZUbkZ4d1A1SXN0eEg2WDBlT1pxNDlxbjNHYVI0Vk9oUDA4NDJIOHdjQlgtRjNrLVViVU1GcUxCTWZMVnpaeUNXRnhMeDVJSThFNnpqYzhxTTd3UjJfUnpjWXU2bWJnME1RbzZfV2FNZWZuRWJpRkhfVG0xMXJuTEthYTA3NUI4OWhHVlVidjNzR2w1Y0psUmU4V1R3VkhOZHdyMWhjOEhkQk0wMkIxZ0V1UjAyUmM3OFhvQlZvN3RIRF9abnNzM09uRFdFeFJoalphVDZMRHVWN0VIZzRR?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals Stock (RXRX) Opinions on ARK Invest's Recent Share Purchase", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQy1EQkxoUVlXN3czcHk1d0c5TlZ5b25fWm1hZ01ZUVFCc0xOekxtZ3Zwc0Vjc3lLWFVqZ1ZsLVQ5eXhqb1EwVm90cDIxd3hEc1BuZG1vMVd3ZVdRemlPMVpFTjl3OTlYTEFjN0dvYjZiY1M0NC11UEJtWm9VNG1Pb2NyWERrMUpVSkdpaGUzdDBTTUluSHFGRThvN29SWmVxVUVlZzFiNnExU0ZSb0hvMkVHMzEta1dHbkN0a01SWHhRUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:RXRX)", "summary": "This article provides an overview of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions regarding the stock's ticker, price volatility, earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-RXRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:57", "published_display": "26 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8RL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Recursion Pharmaceuticals, Inc. Class A (8RL) stock, including a price target of 5.69 EUR based on analyst estimates. It outlines key financial metrics such as recent earnings and revenue, and provides information on employee count and EBITDA.", "url": "https://www.tradingview.com/symbols/SWB-8RL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:57", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals Stock Short Interest Rises to 36.75% | RXRX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPUWFqcTBzYVpDV2ZOd0xLb0Z2R3l1X09TcXI3X01vbnFRd1dhRzh2RnZCaF9ubHlrc1VscTBNMUllOWZ2N09pZkxIVy1RbllYVFBsSDZ3ZVZDR1kwTTBTTi1FdzZkMFQ5NmMyUU9MUHF5RFhwNExDSTI4dFVRZU53bnV3dVY3dVg3eW5fMWZmdGxjMmFiQVM1OUZrcnlEQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Recursion Pharmaceuticals, Inc. (RXRX) stock, including analyst price targets and ratings. It details the company's financial performance, such as recent earnings and revenue, and answers common questions about its stock performance, market ca", "url": "https://www.tradingview.com/symbols/BX-RXRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T04:09:24", "published_display": "26 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOOEpKOENaUGtoTm5xaVdTLVdhSENyZjBxeUVyYUs3Q3NhTlk0bkRpUFdZRTFfWUw3WnMxcS1LSVNxUC15em4tZzJsQmxzeWJESWVLT1FkX1VFcVN1MmRvX3I0VXpTSjJMdWxLYVlmZTFyTXpQN25SU0hRWG8zWUVkNjFVVWRqWXduc1ZnTmRSQVQ5em1HTzVhN0l0enBWRUtoNTJDaVY0c2VtYVk4aXc?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director receives 88,424-share restricted stock grant", "summary": "Recursion Pharmaceuticals (NASDAQ: RXRX) director Robert Hershberg was granted 88,424 restricted stock units (RSUs) as a routine award under the company\u2019s Outside Director Compensation Policy. These RSUs vest on the earlier of June 17, 2027, or the day before the company\u2019s 2027 a", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-029d56158593.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:26", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director gets 88,424 RSUs, sells 3,963 shares", "summary": "Recursion Pharmaceuticals, Inc. director Namandje Bumpus received a grant of 88,424 restricted stock units (RSUs) on June 17, 2026, which vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholders\u2019 meeting. Concurrently, on June 18, 2026, Bumpus sold 3,9", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-2dd9159873a3.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:12:35", "published_display": "23 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director Elaine Sun receives 88,424 restricted stock units", "summary": "Recursion Pharmaceuticals (NASDAQ: RXRX) director Elaine Sun has been granted 88,424 restricted stock units (RSUs) as an equity award, with no cash cost, under the company\u2019s Outside Director Compensation Policy. These RSUs will vest on the earlier of June 17, 2027, or the day bef", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-ce95735cbb59.html", "source_name": "Stock Titan", "published_at": "2026-06-23T01:39:26", "published_display": "23 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (RXRX) director Zavain Dar granted 88,424 restricted stock units", "summary": "Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 88,424 restricted stock units (RSUs) for board service. These RSUs, valued at $0.00 per share, will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholder meeting, contingent on continue", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-dc80c6c6cf27.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:26", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director gets 88,424 restricted stock units", "summary": "Recursion Pharmaceuticals (NASDAQ: RXRX) director Franziska Michor was granted 88,424 restricted stock units as compensation under the company's Outside Director Compensation Policy. These units were granted at $0.00 per share and will vest on June 17, 2027, or the day before the", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-8d1c13cf7754.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:26", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) director Dean Y. Li granted 88,424 RSUs, updates holdings", "summary": "Recursion (NASDAQ: RXRX) director Dean Y. Li was granted 88,424 restricted stock units (RSUs) as part of the company's Outside Director Compensation Policy. These RSUs, valued at $0.00 per share, are set to vest on June 17, 2027, or the day before the 2027 Annual Meeting of Stock", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-54f57d2b93ef.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:26", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (RXRX) director receives 88,424 restricted stock units award", "summary": "Recursion Pharmaceuticals (RXRX) director Blake Borgeson was granted 88,424 restricted stock units of Class A common stock under the company\u2019s Outside Director Compensation Policy. These units will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholde", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-053e24d8f932.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:26", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Proxy filing Summary", "summary": "Recursion Pharmaceuticals (RXRX) will hold its annual meeting virtually on June 17, 2026, where shareholders will vote on the election of two Class II directors, executive compensation, and auditor ratification. The company, a clinical-stage TechBio firm, uses AI for drug discove", "url": "https://quartr.com/events/recursion-pharmaceuticals-inc-rxrx-proxy-filing_oje5fnnj", "source_name": "Quartr", "published_at": "2026-06-20T00:39:34", "published_display": "20 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) investors back board nominees and PwC as 2026 auditor", "summary": "Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shareholders approved all management proposals at their 2026 annual meeting on June 17, 2026. Shareholders re-elected Class II directors Najat Khan, Ph.D., and Franziska Michor, Ph.D., and advisory approved executive compensation. Th", "url": "https://www.stocktitan.net/sec-filings/RXRX/8-k-recursion-pharmaceuticals-inc-reports-material-event-89f780a220d1.html", "source_name": "Stock Titan", "published_at": "2026-06-19T00:39:34", "published_display": "19 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX (NASDAQ) proposed resale of multiple 40,000-share blocks between Mar\u2013Jun 2026", "summary": "RXRX (Recursion Pharmaceuticals, INC.) has filed a Form 144, indicating proposed resales of Class A founder shares. The filing details multiple 40,000-share blocks with potential trade dates spanning from March to June 2026, each with an associated dollar value. Fidelity Brokerag", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-c9a2980302a5.html", "source_name": "Stock Titan", "published_at": "2026-06-19T00:09:59", "published_display": "19 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Christopher C. Gibson sells six 40,000-share lots (RXRX) across Mar\u2013Jun 2026", "summary": "Christopher C. Gibson, an insider at Recursion Pharmaceuticals (RXRX), filed a Form 144 detailing six separate sales of 40,000 Class A shares each between March and June 2026. The filing also indicates scheduled restricted stock vesting events for Class A shares in 2025 and 2026.", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-fc478c99337b.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:09:20", "published_display": "18 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RXRX (NASDAQ) affiliate files Form 144 to sell 3,963 Class A shares", "summary": "An affiliate of Recursion Pharmaceuticals (RXRX) has filed a Form 144, indicating an intent to sell 3,963 Class A shares resulting from restricted stock vesting on June 18, 2026. This filing also discloses a prior sale of 4,386 Class A shares by Namandje Bumpus on June 3, 2026. T", "url": "https://www.stocktitan.net/sec-filings/RXRX/144-recursion-pharmaceuticals-inc-sec-filing-b9f26ac2a192.html", "source_name": "Stock Titan", "published_at": "2026-06-18T13:40:32", "published_display": "18 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion (NASDAQ: RXRX) CFO covers taxes with 5,396 withheld shares", "summary": "Recursion Pharmaceuticals' CFO, Ben R. Taylor, reported a tax-related disposition where 5,396 shares of Class A Common Stock were withheld to cover tax obligations stemming from restricted stock units. The shares were withheld at a price of $3.15 per share. Following this transac", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-d55499100731.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:10:36", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Stock Could Be 67% Overvalued After Pipeline Updates", "summary": "Recursion Pharmaceuticals (RXRX) is gaining attention due to recent clinical updates and an upcoming presentation at the Goldman Sachs Global Healthcare Conference, leading to a recent share price increase. Despite this, some analyses suggest the stock is significantly overvalued", "url": "https://www.sahmcapital.com/news/content/recursion-pharmaceuticals-rxrx-stock-could-be-67-overvalued-after-pipeline-updates-2026-06-16", "source_name": "Sahm", "published_at": "2026-06-16T12:40:35", "published_display": "16 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Early Safety Data And FDA Signals Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX)", "summary": "Recursion Pharmaceuticals' investment case is being reshaped by early safety data for REC-1245 in solid tumors and anticipated FDA feedback on REC-4881, which are key catalysts for its AI-driven drug discovery platform. While the initial safety profile of REC-1245 is positive, in", "url": "https://www.sahmcapital.com/news/content/early-safety-data-and-fda-signals-might-change-the-case-for-investing-in-recursion-pharmaceuticals-rxrx-2026-06-13", "source_name": "Sahm", "published_at": "2026-06-13T23:10:36", "published_display": "13 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock", "summary": "Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of RXRX stock totaling $84,459 on June 5, 2026, through a pre-planned trading arrangement. Despite this sale, Khan still holds over 2.1 million shares, and the company is considered undervalued by InvestingPro. The compa", "url": "https://www.investing.com/news/insider-trading-news/recursion-pharmaceuticals-ceo-najat-khan-sells-84459-in-rxrx-stock-93CH-4729290", "source_name": "Investing.com", "published_at": "2026-06-08T08:10:18", "published_display": "08 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After Positive AI Drug Data And Extended Cash Runway", "summary": "Recursion Pharmaceuticals (RXRX) saw its stock rise by 9.5% following positive early clinical data from its AI-driven drug discovery programs and a reduced cash burn, extending its capital runway into early 2028. This progress suggests its integrated TechBio model is yielding tan", "url": "https://www.sahmcapital.com/news/content/why-recursion-pharmaceuticals-rxrx-is-up-95-after-positive-ai-drug-data-and-extended-cash-runway-2026-06-04", "source_name": "Sahm", "published_at": "2026-06-06T08:40:12", "published_display": "06 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com", "summary": "Najat Khan, CEO of Recursion Pharmaceuticals, sold 23,588 shares of RXRX stock for $84,459 on June 5, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, Khan directly holds over 2.17 million shares, and the company has a market cap of $1.77 billion. The article also", "url": "https://m.za.investing.com/news/insider-trading-news/recursion-pharmaceuticals-ceo-najat-khan-sells-84459-in-rxrx-stock-93CH-4316803?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-06T08:10:34", "published_display": "06 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) CEO sells 23,588 shares in planned Rule 10b5-1 trade", "summary": "Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of Class A Common Stock at a weighted average price of $3.5806 per share under a pre-arranged Rule 10b5-1 trading plan. After the sale, Khan still directly holds a significant 2,175,796 shares. This transaction, detailed", "url": "https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-aa40cd8c382f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:39:40", "published_display": "05 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxObk5Dbkc3Y0xPSURiQVFuRzRHdHl2b0dDMEIzM3ZrN2x3ZDlKNFA1b1FPRHpMb2Z3MnBKV1NTdzMxSG5FNXpWT1JQd1JCR3NhVF9FZzZSeDZkeFhHSTUxcFVkRVY4Tm5pUEFjRXI4eE5IWW1YRktYUFg3ejZJcU9tNHhjanZ2eXNRT2FTRzdDZTJGUERWdXQ5VUljbDdjZTVPdmc?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America Securities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOQnI4aGFtR0FiYjgxM2d4UUZhRk4wLUFKc1VYejNQRkxYTW54dnROZHlYbG5hbndGd1FtVHdYbFRxUEJRcGJicVIyTExsZkdUeGhpc19xYU1RUUk5YkNSVnZUTXJSNzcyX1VWNFlhWTdPNjJmZFlsMkZuOFI5QmhGdG1obzJwVk9LSWdKWTlNbnYtTEhwVG9ZSUU1MWlDY1RwRzZPYTBSNGpza1g5S3V6b0ZRS0N3cXYtTXNrc1lGM2dWTEdHdVVLTk00VlZ1ZHJMNTdGTW9pcXFPQUN3cVduTDlhSlNwVnpkVFRYU1pvQ284aEhvMUE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion\u2019s AI Drug Programs Show Early Clinical Progress And Valuation Gap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals (RXRX) Q1 Loss Of US$117.5 Million Tests AI Growth Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNUDVWNGhGVnJrNW5XVXdkd1BmTU9LdUY0LXZ0UGVWak1KSmh4Uy01bkkyeWhaTkRPbkh2WnNSYllpRHlnVlV3d05FWF9UOEZZb3N0UlRSX24xeHd0X3dnMy0tTmRCaUtkdDFjZEtIajlyc3RBMFZZQU9QNTBEcVJDRVpuQ19CVlJQb2ltb2lTOFVEZGs2aUNiUVhZQVRjZWQ0QjRzQk5pMGE0a050RlZNTkpONE9MeE8yZWxMRW8yaUdCLXYwbVgwc3ZpTEJRa084WUcycHZUVFJSeE5FMVZyTzhjWEp4RGlKdUlHbFJsY0PSAfYBQVVfeXFMT3lFVHVyRmdVejZBU3B4YUJoWkt4UTJ1RHlmZzk5ZFBVX2pkN25TRWR2NGVzVUl5YU5EX3lCM0Q2MjROeGFJRGZ1d05XczdBM25xNmJBRDBoVERyN3pXeDVUTDJJbWxXaEh1WGlfYTlyY2FiTzJ5Y0p1RnhxTEFKczJxRUY5RGtWN2V2cHV2cjdqVThVN2dNOGdBN1Z4SWNrTzlDcm1jM1JVTm5hSE5rd3VyYlVDNmJlQk1RWGlvUjFnYTUtU1FVdXBvdE5vM2wzSDlrVTdYR1NwRHp2ZW8zZzlKQkxtRWxXYXU3NVBaT3JpbVNobVNB?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMHotNUpHUWhhaFJlWUdXcHAxdDdsLU9QbG9TYm9Vek9ZNTAyVHdCUTR5c3lqZHhfbDJMVTFZMkkzcG40Q0YtdURBa0g3Q096TDJzUkhfMEY2bDA4d3NnM0lpSDBlYjdtVmVyNWM5WFZBeDFkYTFSZnMtdVc0WFVfQXpPaGR4VWhHdVFneEV6bnRESy1hY1paZzRqTHpFY3BuTHhtdDM1RzRIYWI3TFRpUw?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Wide Valuation Range After Recent Volatility", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Christopher Gibson sells Class A shares (NASDAQ: RXRX) in four filings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNnFGT1VVcXpVeDlPdWhEYXRhMmFGTnpwczc5b1BUejRBTFk5dEZJdEZQZmp4WTM1QXdIV2xTVUN6YjVFODlaT2xtOU5uNGU1Rk1nUVFUV255TmJ6Nnl2NlI3dW5oV3hMdzNhRzh1RDd1cHNvZWJWdUF6TEZ2cWNXQzlpVUlzZ0VHSmwtSjBWVG15S3pVTzd2bnpUcmxaLURJWGJUM2Zoc1V3QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 108, "total_relevant": 70, "sentiment_summary": {"positive": 14, "negative": 8, "neutral": 48, "score": 52, "total": 70, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 28.4, "count": 51}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 14, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 3.56, "latest_week": "2026-07-10", "one_week_move": -6.3, "four_week_move": 13.0, "twelve_week_move": -5.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.16334, "market_dynamics_buy_signal": false, "relative_strength": -29.287117, "fair_value_gap": -46.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 47.2425, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.3% over one week, +13.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 19}, {"label": "Market source", "count": 11}, {"label": "simplywall.st", "count": 7}, {"label": "TradingView", "count": 4}, {"label": "Quiver Quantitative", "count": 4}, {"label": "Sahm", "count": 3}, {"label": "Motley Fool", "count": 2}, {"label": "Stocktwits", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 62}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 51}, {"label": "Earnings", "count": 14}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "62", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.3% over one week, +13.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today"}], "updated_at": "2026-07-16T04:34:22.494463+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}